XML 31 R19.htm IDEA: XBRL DOCUMENT

Equity Incentive Plans (Tables)

6 Months Ended

Jun. 30, 2018

Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]

A summary of the status of the Company’s option plans as of June 30, 2018 and changes during the period then ended is presented below:

	Six months ended June 30, 2018
	Unaudited
	Number of options			Weighted average exercise price
Outstanding at beginning of year		14,806,027		$	10.64
Granted		2,199,389			22.31
Exercised		(2,253,654	)		6.54
Forfeited and cancelled		(127,262	)		14.59
Outstanding as of June 30, 2018		14,624,500		$	12.99

Exercisable options		5,955,869		$	10.20

Schedule of RSU's

A summary of the status of the Company’s RSUs as of June 30, 2018 and changes during the period then ended is presented below:

	Six months ended June 30, 2018
	Unaudited
	Number of RSUs			Weighted average grant date fair value price
Unvested at beginning of year		1,651,219		$	9.66
Granted		482,232			22.20
Vested		(550,418	)		9.66
Forfeited and cancelled		(10,760	)		12.13
Unvested as of June 30, 2018		1,572,273		$	13.49

Schedule of Fair Value Assumptions Used for All Equity Based Awards Estimated Using Black-Scholes Option Pricing Model

The fair value of share-based awards was estimated using the Black-Scholes model for all equity grants. For market condition awards, the Company also applied the Monte-Carlo simulation model, with the following underlying assumptions:

	Six months ended June 30,		Year ended December 31,
	2018	2017	2017
	Unaudited		Audited
Stock Option Plans
Expected term (years)	5.50-6.25	5.50-6.25	5.50-6.25
Expected volatility	52%-55%	57%-59%	57%-59%
Risk-free interest rate	2.70%-2.89%	1.99%-2.23%	1.97%-2.23%
Dividend yield	0.00%	0.00%	0.00%
ESPP
Expected term (years)	0.50	0.50	0.50
Expected volatility	53%	82%	76%-82%
Risk-free interest rate	1.61%	0.62%	0.62%-1.13%
Dividend yield	0.00%	0.00%	0.00%

Schedule of Non-cash Share-based Compensation Expense Related to Company's Equity-Based Awards

The total non-cash share-based compensation expense related to all of the Company’s equity-based awards recognized for the three and six months ended June 30, 2018 and 2017 and the year ended December 31, 2017 was:

	Three months ended June 30,				Six months ended June 30,				Year ended December 31,
	2018		2017		2018		2017		2017
	Unaudited				Unaudited				Audited
Cost of revenues	$	263	$	131	$	428	$	274	$	467
Research, development and clinical trials		1,286		811		2,192		1,673		3,587
Sales and marketing		1,893		1,735		3,329		2,390		3,784
General and administrative		6,764		4,893		12,777		7,794		19,278
Total share-based compensation expense	$	10,206	$	7,570	$	18,726	$	12,131	$	27,116